To determine whether there is a significant reduction in frequency and severity of hot flashes in symptomatic postmenopausal women who are administered continuously different dose combinations of norethindrone acetate and ethinyl estradiol.
Two randomized clinical trials (Study 1 and Study 2) were conducted in which study participants recorded in daily diaries the frequency of their hot flashes. Study 2 participants also recorded the number of mild, moderate, or severe hot flashes they experienced. In Study 1, a total of 219 postmenopausal women reporting vasomotor symptoms were placed randomly into groups to receive either a placebo or 1 of 4 treatments (0.2 mg /1 μg; 0.5 mg/2.5 μg; 1 mg/5 μg; or 1 mg/10 μg norethindrone acetate/ethinyl estradiol). In Study 2, a total of 266 highly symptomatic postmenopausal women were placed randomly to receive either a placebo or 1 of 3 treatment groups [0.5 mg/2.5 μg; 1 mg/5 μg; or 1 mg/10 μg norethindrone acetate (NA)/ethinyl estradiol (EE)]. Total duration of treatment was 16 weeks in Study 1 and 12 weeks in Study 2. Study 1 subjects had to have at least 10 hot flashes during the week before randomization. Study 2 subjects had to have at least 56 moderate to severe hot flashes during the week before randomization.
In both studies, there was a dose-related decrease in hot flash frequency with the highest dose (1 mg NA/10 μg EE) group that had the greatest response. Significant differences from placebo (p < 0.05, Dunnett's test) occurred within 4 weeks in Study 1 for hot flash frequency with a percent reduction in frequency ranging from 33% for placebo to 84% for both the 1 mg NA/10 μg EE and 1 mg NA/5 μg EE dose groups. Likewise, Study 2 significant reductions in hot flash frequency occurred by Week 2 for 1 mg NA/10 μg EE, Week 3 for 1 mg NA/5 μg EE, and Week 5 for 0.5 mg NA/2.5 μg EE (p < 0.05, Dunnett's test). This dose effect was also apparent with regard to severity. In addition, more subjects had clinically meaningful reductions in hot flash frequency or elimination as the dose combinations increased.
There were significant reductions in hot flash frequency and severity with continuous treatment with norethindrone acetate and ethinyl estradiol combinations. The time at which significant reductions were observed, as well as the magnitude of the response, were dose dependent. The opportunity for lower-dose options of a new continuous-combined hormone replacement therapy provides therapeutic flexibility for women who are recently menopausal.
From the 1Oregon Health Sciences University, Portland, Oregon; and 2Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan, USA.
Received February 22, 2000; revised and accepted May 26, 2000.
Address reprint requests to: James Symons, PhD, Parke-Davis Pharmaceutical Research, 2800 Plymouth Road., Ann Arbor, MI 48105, USA.
The femhrt® Study Investigators: M.C. Burton, MD, Mark P. Cohen, MD, Richard Hebertson, MD, Leon Speroff, MD, Robert Stillman, MD, Steven C. Voss, MD, Elizabeth L. Evans, MD, William H. Swartz, MD, Herbert Soper, MD, Jon Ruckle, MD, Steven Williams, MD, Simona Scumpia, MD, Edwin Bronsky, MD, Frank Mazzone, MD, Margaret Drehobl, MD, Sherwyn Schwartz, MD, Morton Rosenstein, MD, John Mattox, MD, Stephen F. Gordon, MD, James D. Smith MD, Helmut Schrott, MD, Troy Williams, MD, Ira Weisberg, MD, Mildred Farmer, MD, Steven Zeig, MD, Louis Cohen, MD, John A. Holmes, MD, Harvey Resnick, MD, Richard E. Hedrick, Jr., MD, John P. Lenihan, MD, Robert B. Jacobson, MD, Ronald Coe, MD, Robert H. Friedman, MD.